Dr. Chris Venner completed his medical training at the University of Calgary and the University of Alberta. He later attended the University of British Columbia to complete a sub-specialty degree in Hematology. He then went on to pursue a Plasma Cell Dyscrasias Fellowship jointly through the Leukemia/Bone Marrow Transplant Program of British Columbia, St. Bartholomew’s Hospital and the London School of Medicine and the National Amyloidosis Centre. He subsequently joined the National Amyloid Centre as a staff physician before returning to Edmonton and the Cross Cancer Institute and led the Malignant Hematology Program and the Myeloma/Plasma Cell Dyscrasias group. In 2021 he joined the BC Cancer – Vancouver Centre to advance the Plasma Cell Dyscrasias Program. In addition to being actively involved in hematology clinical trials, his current academic interest involves clinical outcomes research in plasma cell dyscrasias, examining the evolution of therapy in these diseases and the impact novel combinations have on survival. Much of this work is done through the Canadian Myeloma Research Group through activities in the CMRG Canadian Multiple Myeloma Database initiative which he led as Chair (2014-2021), and the CMRG clinical trials group. He is also the Co-Chair of the Myeloma Sub-Committee with the Canadian Cancer Trials Group.